Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - wafer - excipient ingredients: glycine; gelatin; mannitol; aspartame; flavour - maxalt is indicated for the acute treatment of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - wafer - excipient ingredients: glycine; mannitol; gelatin; aspartame; flavour - maxalt is indicated for the acute treatment of migraine attacks with or without aura.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan 10 mg - maxalt® and maxalt-mlt® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use - maxalt should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with maxalt, the diagnosis of migraine should be reconsidered before maxalt is administered to treat any subsequent attacks. - maxalt is not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)] . - maxalt is not indicated for the prevention of migraine attacks. - safety and effectiveness of maxalt have not been established for cluster headache. maxalt is contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see warnings and precautions (5.1)] . - coronary artery vasospasm including prinzmetal's

United States - English - NLM (National Library of Medicine)

organon llc - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - maxalt® and maxalt-mlt® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use - maxalt should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with maxalt, the diagnosis of migraine should be reconsidered before maxalt is administered to treat any subsequent attacks. - maxalt is not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)] . - maxalt is not indicated for the prevention of migraine attacks. - safety and effectiveness of maxalt have not been established for cluster headache. maxalt is contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see warnings and precautions (5.1)] . - coronary artery vasospasm including prinzmetal's

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan 5 mg - maxalt® and maxalt-mlt® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use - maxalt should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with maxalt, the diagnosis of migraine should be reconsidered before maxalt is administered to treat any subsequent attacks. - maxalt is not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)] . - maxalt is not indicated for the prevention of migraine attacks. - safety and effectiveness of maxalt have not been established for cluster headache. maxalt is contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see warnings and precautions (5.1)] . - coronary artery vasospasm including prinzmetal's

United States - English - NLM (National Library of Medicine)

stat rx usa llc - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate 5 mg - maxalt is indicated for the acute treatment of migraine attacks with or without aura in adults. maxalt is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of maxalt have not been established for cluster headache, which is present in an older, predominantly male population. maxalt should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal’s variant angina, or other significant underlying cardiovascular disease (see warnings). because maxalt may increase blood pressure, it should not be given to patients with uncontrolled hypertension (see warnings). maxalt should not be used within 24 hours of treatment with another 5-ht1 agonist, or an ergotamine-containing or ergot-type

United States - English - NLM (National Library of Medicine)

rebel distributors corp - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate 10 mg - maxalt is indicated for the acute treatment of migraine attacks with or without aura in adults. maxalt is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of maxalt have not been established for cluster headache, which is present in an older, predominantly male population. maxalt should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal’s variant angina, or other significant underlying cardiovascular disease (see warnings). because maxalt may increase blood pressure, it should not be given to patients with uncontrolled hypertension (see warnings). maxalt should not be used within 24 hours of treatment with another 5-ht1 agonist, or an ergotamine-containing or ergot-type

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rizatriptan benzoate, quantity: 7.265 mg - wafer - excipient ingredients: gelatin; aspartame; glycine; mannitol; flavour - for the acute relief of migraine in patients who have a stable, well-established pattern of migraine symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - rizatriptan benzoate -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - rizatriptan benzoate 14.53mg equivalent to 10 mg rizatriptan - wafer - 10 mg - active: rizatriptan benzoate 14.53mg equivalent to 10 mg rizatriptan excipient: aspartame gelatin glycine mannitol mentha x piperita purified water - for the acute treatment of migraine attacks with or without aura.